316 related articles for article (PubMed ID: 10352255)
1. Expression of multiple unique rejection antigens on murine leukemia BALB/c RLmale symbol1 and the role of dominant Akt antigen for tumor escape.
Matsuo M; Wada H; Honda S; Tawara I; Uenaka A; Kanematsu T; Nakayama E
J Immunol; 1999 Jun; 162(11):6420-5. PubMed ID: 10352255
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with multiple antigen peptide as rejection antigen peptide in murine leukemia.
Manki A; Ono T; Uenaka A; Seino Y; Nakayama E
Cancer Res; 1998 May; 58(9):1960-4. PubMed ID: 9581839
[TBL] [Abstract][Full Text] [Related]
3. Occurrence of tumor antigen pRL1a specific CD8 T cells in spleen cells from syngeneic BALB/c, semiallogeneic (BALB/c x C57BL/6)F1 and allogeneic C57BL/6 mice.
Hata H; Uenaka A; Takada I; Kenjo A; Takahashi M; Ono T; Fujita T; Nakayama E
Int J Oncol; 2002 May; 20(5):1019-25. PubMed ID: 11956599
[TBL] [Abstract][Full Text] [Related]
4. Rejection antigen peptides on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes: derivation from the normally untranslated 5' region of the c-akt proto-oncogene activated by long terminal repeat.
Wada H; Matsuo M; Uenaka A; Shimbara N; Shimizu K; Nakayama E
Cancer Res; 1995 Nov; 55(21):4780-3. PubMed ID: 7585504
[TBL] [Abstract][Full Text] [Related]
5. Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice.
Manning TC; Rund LA; Gruber MM; Fallarino F; Gajewski TF; Kranz DM
J Immunol; 1997 Nov; 159(10):4665-75. PubMed ID: 9366389
[TBL] [Abstract][Full Text] [Related]
6. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
Sensi M; Orosz CG; Bach FH
J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
[TBL] [Abstract][Full Text] [Related]
7. Reduced diversity of CTLs specific for multiple minor histocompatibility antigens relative to allograft rejection in vivo.
Nevala WK; Paul C; Wettstein PJ
J Immunol; 1997 Feb; 158(3):1102-7. PubMed ID: 9013948
[TBL] [Abstract][Full Text] [Related]
8. Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene.
Uenaka A; Ono T; Akisawa T; Wada H; Yasuda T; Nakayama E
J Exp Med; 1994 Nov; 180(5):1599-607. PubMed ID: 7964448
[TBL] [Abstract][Full Text] [Related]
9. H-2 antigens and tumour-associated transplantation antigens in clones derived from a methylcholanthrene-induced BALB/c tumour: their influence on the generation in vitro and in vivo of the specific anti-tumour immune response.
Pérez M; Garrido A; Algarra I; Caballero A; Delgado C; Collado MD; Fernández-Cruz E; Garrido F
Exp Clin Immunogenet; 1989; 6(3):204-18. PubMed ID: 2631798
[TBL] [Abstract][Full Text] [Related]
10. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts.
Nagata Y; Furugen R; Hiasa A; Ikeda H; Ohta N; Furukawa K; Nakamura H; Furukawa K; Kanematsu T; Shiku H
J Immunol; 1997 Aug; 159(3):1336-43. PubMed ID: 9233630
[TBL] [Abstract][Full Text] [Related]
11. Production of murine leukemia RLmale1 rejection antigen peptide pRL1a by proteolysis of natural precursor pRL1b.
Ono T; Uenaka A; Nakayama E
Jpn J Cancer Res; 1996 Nov; 87(11):1165-70. PubMed ID: 9045946
[TBL] [Abstract][Full Text] [Related]
12. Cell-mediated anti-tumor response in the RLmale 1 system. II. Control of the T killer cells by an H-2-linked Ir gene interfering with non-H-2 factors.
Duprez V; Belucchi S; Lévy JP
Eur J Immunol; 1980 Jan; 10(1):26-30. PubMed ID: 6767612
[TBL] [Abstract][Full Text] [Related]
13. Effector mechanisms of syngeneic anti-tumour responses in mice. II. Cytotoxic T lymphocytes mediate neutralization and rejection of radiation-induced leukaemia RL male 1 in the nude mouse system.
Keyaki A; Kuribayashi K; Sakaguchi S; Masuda T; Yamashita J; Handa H; Nakayama E
Immunology; 1985 Sep; 56(1):141-51. PubMed ID: 3876272
[TBL] [Abstract][Full Text] [Related]
14. Detection of a unique antigen on radiation leukemia virus-induced leukemia B6RV2.
Nakayama E; Uenaka A; Stockert E; Obata Y
Cancer Res; 1984 Nov; 44(11):5138-44. PubMed ID: 6091870
[TBL] [Abstract][Full Text] [Related]
15. H-40, an antigen controlled by an Igh-linked gene and recognized by cytotoxic T lymphocytes. II. Recognition of H-40 as a tumor antigen in leukemic animals.
Henderson LA; Ciavarra R; Riblet R; Forman J
J Immunol; 1984 Nov; 133(5):2778-85. PubMed ID: 6434638
[TBL] [Abstract][Full Text] [Related]
16. Development and antigen specificity of CD8+ cytotoxic T lymphocytes in beta 2-microglobulin-negative, MHC class I-deficient mice in response to immunization with tumor cells.
Apasov SG; Sitkovsky MV
J Immunol; 1994 Mar; 152(5):2087-97. PubMed ID: 8133027
[TBL] [Abstract][Full Text] [Related]
17. Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96.
Ishii T; Udono H; Yamano T; Ohta H; Uenaka A; Ono T; Hizuta A; Tanaka N; Srivastava PK; Nakayama E
J Immunol; 1999 Feb; 162(3):1303-9. PubMed ID: 9973383
[TBL] [Abstract][Full Text] [Related]
18. Induction of peptide-specific CD8+ CTL clones in beta 2-microglobulin-deficient mice.
Cook JR; Solheim JC; Connolly JM; Hansen TH
J Immunol; 1995 Jan; 154(1):47-57. PubMed ID: 7995959
[TBL] [Abstract][Full Text] [Related]
19. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb.
Ito D; Ogasawara K; Iwabuchi K; Inuyama Y; Onoé K
J Immunol; 2000 Feb; 164(3):1230-5. PubMed ID: 10640735
[TBL] [Abstract][Full Text] [Related]
20. Analysis of CD8 T-cell response by IFNgamma ELISPOT and H-2L(d)/pRL1a tetramer assays in pRL1a multiple antigen peptide-immunized and RL male 1-bearing BALB/c and (BALB/c x C57BL/6) F(1) mice.
Takada I; Noguchi Y; Kenjo A; Wada H; Uenaka A; Fujita T; Inoue H; Nakayama E
Cancer Sci; 2004 Mar; 95(3):254-9. PubMed ID: 15016326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
